Company could have enough late-stage trial data by October to evaluate its efficacy
THURSDAY, Sept. 17, 2020 (HealthDay News) — Moderna says it should know by sometime in November whether its COVID-19 vaccine is effective, its CEO said Thursday.
Stephane Bancel also told CNBC that the company — the first drug firm to conduct human clinical trials of a COVID-19 vaccine in the United States — could have enough late-stage trial data by October to evaluate its efficacy but said it is unlikely, CBS News reported. Along with Moderna’s vaccine, there are six others in final phase 3 testing that involves large-scale human tests.
“If the infection rate in the country were to slow down in the next weeks, [the vaccine] could potentially be pushed out in a worst-case scenario in December,” Bancel told CNBC, CBS News reported.
On Wednesday, U.S. Centers for Disease Control and Prevention Director Robert Redfield, M.D., told Congress a vaccine would not be widely available until the second or third quarter of next year. Redfield also said a mask could be even more effective protection than a vaccine for people who do not have an immunity response from the vaccine, CBS News reported. A “face mask is more guaranteed to protect me against COVID than when I take a COVID vaccine,” Redfield said. “Â… If I don’t get an immune response, the vaccine’s not going to protect me. This face mask will.”
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Trends Reported in Vaccination Coverage for Adolescents for 2025
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer
Retinal Imaging Can ID Atrial Fibrillation Years Before Diagnosis
U.S. Adults May Not Understand Their Risk for Vascular Disease
Lower Breast, Cervical Cancer Screening Seen for Adults With Disabilities
Screening + Online Cognitive Behavioral Therapy Program Aids Nurses" Mental Health